Interestingly, an exploratory analysis showed a significant advantage for patients with PD-L1-positive TNBC and for those with CD274 gain/amplification, while tumor infiltration by lymphocytes (CD8, FoxP3 and CD103 expressions) and homologous recombination deficiency were not associated with sensitivity to durvalumab [64]. Here, CD274 is linked to neoplasm.